Famotidin-BP (tab)

Famotidinum

Each tablet contains famotidine 20 mg or 40 mg. Excipient with known effect: lactose monohydrate.

Indication: Active gastroduodenal ulcer; prevention of duodenal ulcer recurrence; reflux oesophagitis; Zollinger-Ellison syndrome.

Contraindications (SmPC sec. 4.3): 4.3 Contraindications Hypersensitivity to famotidine or to any of the excipients. Pregnancy and breast-feeding.

Special warnings and precautions (SmPC sec. 4.4, excerpt): 4.4 Special warnings and precautions for use Cross-hypersensitivity Cross-hypersensitivity reactions have been observed between different H2-receptor antagonists; caution is required in patients with a history of hypersensitivity to other substances of this class. Gastric cancer In patients with gastric ulcer, the benign nature of the lesion should be confirmed before starting treatment and, if necessary, during treatment. Symptomatic improvement with famotidine treatment does not exclude the presence of gastric malignancy. Renal impairment Since famotidine is excreted mainly via the renal route, caution and dose reduction are required in patients with renal impairment and creatinine clearance below 30 mL/min (see section 4.2). Hepatic impairment In patients with hepatic impairment, as well as in […]